Literature DB >> 12392790

The p38 pathway is activated in Pick disease and progressive supranuclear palsy: a mechanistic link between mitogenic pathways, oxidative stress, and tau.

Anthony W Hartzler1, Xiongwei Zhu, Sandra L Siedlak, Rudolph J Castellani, Jesus Avilá, George Perry, Mark A Smith.   

Abstract

In Pick disease and progressive supranuclear palsy (PSP), accumulations of phosphorylated tau are associated with oxidative stress, although the mechanism linking these features remains unknown. However, we suspected that the oxidative stress-induced activation of mitogen-activated protein kinases might lead to tau phosphorylation and accumulation as characteristic inclusion bodies. To test this notion, we investigated whether the activation of mitogen-activated protein kinases is involved in the pathogenesis of Pick disease and PSP. Our results show that the lesions of both Pick disease and PSP are associated with the activation of the p38 pathway (phospho-MKK6 and phospho-p38), one of the best characterized of the mitogen-activated protein kinase pathways. Based on these findings, we propose that the phosphorylation of tau is a direct consequence of the oxidative stress-induced activation of mitogen-activated protein kinases, including p38. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12392790     DOI: 10.1016/s0197-4580(02)00029-5

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  12 in total

1.  Regulation of tau pathology by the microglial fractalkine receptor.

Authors:  Kiran Bhaskar; Megan Konerth; Olga N Kokiko-Cochran; Astrid Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Neuron       Date:  2010-10-06       Impact factor: 17.173

2.  MKK6 phosphorylation regulates production of superoxide by enhancing Rac GTPase activity.

Authors:  Maged M Harraz; Andrea Park; Duane Abbott; Weihong Zhou; Yulong Zhang; John F Engelhardt
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

Review 3.  A novel perspective on tau in Alzheimer's disease.

Authors:  D J Bonda; R J Castellani; X Zhu; A Nunomura; H-g Lee; G Perry; M A Smith
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

4.  P38 activation mediates amyloid-beta cytotoxicity.

Authors:  Xiongwei Zhu; Matthew Mei; Hyoung-Gon Lee; Yang Wang; Jiahuai Han; George Perry; Mark A Smith
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

5.  Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice.

Authors:  I Ferrer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 6.  Gene-environment interplay in neurogenesis and neurodegeneration.

Authors:  Tomás Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

7.  Tau phosphorylation in Alzheimer's disease: potential involvement of an APP-MAP kinase complex.

Authors:  Alyson L Peel; Noah Sorscher; Joseph Y Kim; Veronica Galvan; Sylvia Chen; Dale E Bredesen
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

8.  Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Authors:  Cliona Stack; Shari Jainuddin; Ceyhan Elipenahli; Meri Gerges; Natalia Starkova; Anatoly A Starkov; Mariona Jové; Manuel Portero-Otin; Nathalie Launay; Aurora Pujol; Navneet Ammal Kaidery; Bobby Thomas; Davide Tampellini; M Flint Beal; Magali Dumont
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

Review 9.  Phosphorylated tau: toxic, protective, or none of the above.

Authors:  Rudy J Castellani; Akihiko Nunomura; Hyoung-gon Lee; George Perry; Mark A Smith
Journal:  J Alzheimers Dis       Date:  2008-08       Impact factor: 4.472

10.  The Role of p38 MAPK and Its Substrates in Neuronal Plasticity and Neurodegenerative Disease.

Authors:  Sônia A L Corrêa; Katherine L Eales
Journal:  J Signal Transduct       Date:  2012-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.